1. |
Sakorafas GH, Krespis E, Pavlakis G. Risk estimation for breast cancer development; a clinical perspective [J]. Surg Oncol, 2002; 10(4)∶183.
|
2. |
吴扬, 杨莉, 魏于全. 乳腺癌相关基因的分子遗传学研究进展 [J]. 中华医学遗传学杂志, 2002; 19(2)∶152.
|
3. |
Sorokin P. New agents and future directions in biotherapy [J]. Clin J Oncol Nurs, 2002; 6(1)∶19.
|
4. |
Knutson KL, Bishop MR, Schiffman K, et al. Immunotherapy for breast cancer [J]. Cancer Chemother Biol Response Modif, 2002; 20∶351.
|
5. |
Untch M, Ditsch N, Hermelink K. Immunotherapy: new options in breast cancer treatment [J]. Expert Rev Anticancer Ther, 2003; 3(3)∶403.
|
6. |
Menard S, Fortis S, Castiglioni F, et al. HER2 as a prognostic factor in breast cancer [J]. Oncology, 2001; 61 Suppl 2∶67.
|
7. |
Goldenberg MM. Trastuzumab, a recombinant DNAderived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer [J]. Clin Ther, 1999; 21(2)∶309.
|
8. |
Ligibel JA, Winer EP. Trastuzumab/chemotherapy combinations in metastatic breast cancer [J]. Semin Oncol, 2002; 29(3 Suppl 11)∶38.
|
9. |
Christodoulou C, Klouvas G, Pateli A, et al. Prolonged administration of weekly paclitaxel and trastuzumab in patients with advanced breast cancer [J]. Anticancer Res, 2003; 23(1B)∶737.
|
10. |
Avigan D. Fusions of breast cancer and dendritic cells as a novel cancer vaccine [J]. Clin Breast Cancer, 2003; 3 Suppl 4∶S158.
|
11. |
Pulaski BA, OstrandRosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cellbased tumor vaccines [J]. Cancer Res, 1998; 58(7)∶1486.
|
12. |
Wu Q, Moyana T, Xiang J. Cancer gene therapy by adenovirusmediated gene transfer [J]. Curr Gene Ther, 2001; 1(1)∶101.
|
13. |
Dummer R, Bergh J, Karlsson Y, et al. Biological activity and safety of adenoviral vectorexpressed wildtype p53 after intratumoral injection in melanoma and breast cancer patients with p53overexpressing tumors [J]. Cancer Gene Ther, 2000; 7(7)∶1069.
|
14. |
Bougeret C, VironeOddos A, Adeline E, et al. Cancer gene therapy mediated by CTS1, a p53 derivative: advantage over wildtype p53 in growth inhibition of human tumors overexpressing MDM2 [J]. Cancer Gene Ther, 2000; 7(5)∶789.
|
15. |
Takahashi S, Hatake K, Sugimoto Y. Gene therapy for breast cancer [J]. Gan To Kagaku Ryoho, 2003; 30(4)∶468.
|
16. |
Tallman MS, Gray R, Robert NJ, et al. Conventional adjuvant chemotherapy with or without highdose chemotherapy and autologous stemcell transplantation in highrisk breast cancer [J]. N Engl J Med, 2003; 349(1)∶17.
|
17. |
Harris AL, Zhang H, Moghaddam A, et al. Breast cancer angiogenesisnew approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting [J]. Breast Cancer Res Treat, 1996; 38(1)∶97.
|
18. |
Ranieri G, Gasparini G. Angiogenesis and angiogenesis inhibitors: a new potential anticancer therapeutic strategy [J]. Curr Drug Targets Immune Endocr Metabol Disord, 2001; 1(3)∶241.
|